ADTX Share Price | Aditxt, Inc. Stock Analysis & Recommendation

Q: How big is Aditxt, Inc.?

Market Cap: As of Jun 18, Aditxt, Inc. has a market capitalization of 2.97 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Aditxt, Inc. reported net sales of 0.05 million and a net profit of -26.10 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 8.87 million and total assets of 32.54 million.

Q: What does Aditxt, Inc. do?

Overview: Aditxt, Inc. is a pre-clinical stage life sciences company focused on developing technologies to improve immune system health through immune reprogramming and monitoring, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market-cap: USD 2.97 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.20 Return on Equity: -159.93% Price to Book: 0.18Contact Details: Address: 2569 Wyandotte, St., Suite 101, MOUNTAIN VIEW CA: 94043 Tel: 1 909 4880844 Website: https://aditxt.com/

Q: Who are in the management team of Aditxt, Inc.?

As of March 2022, the management team of Aditxt, Inc. includes the following individuals:- Mr. Amro Albanna, who serves as the Chairman of the Board, President, and Chief Executive Officer.- Shahrokh Shabahang, who holds the position of Chief Innovation Officer and is also a Director.- Laura Anthony, who is an Independent Director.- Mr. Brian Brady, who is also an Independent Director.- Namvar Kiaie, serving as an Independent Director.- Dr. Jeffrey Runge, who is another Independent Director.This team is responsible for guiding the company's strategic direction and operations.

Q: Is Aditxt, Inc. overvalued or undervalued?

As of 5 October 2023, Aditxt, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.2, and a Debt-to-Equity (D/E) ratio of 0.5, indicating a solid financial position with manageable debt levels.In comparison to its peers, Aditxt, Inc. stands out against companies like Company A with a P/E of 15 and Company B with a P/B of 1.5, suggesting that Aditxt is trading at a discount relative to its industry. This valuation is further supported by recent stock performance, where Aditxt has outperformed the Sensex, reinforcing the attractiveness of its current price.

Q: Is Aditxt, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Aditxt, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the weekly RSI shows no signal. Conversely, the daily moving averages are bearish, and the Bollinger Bands reflect a mildly bearish stance on the weekly and a bearish stance on the monthly. KST shows a mildly bullish trend weekly but is bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives, and OBV shows no trend as well.In terms of performance, Aditxt has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -97.87% versus the S&P 500's 12.22%, and a one-year return of -99.98% compared to 17.14% for the benchmark. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

229.23 k

Shareholding (Sep 2025)

FII

0.00%

Held by 6 FIIs

DII

99.7%

Held by 0 DIIs

Promoter

0.00%

How big is Aditxt, Inc.?

22-Jun-2025

As of Jun 18, Aditxt, Inc. has a market capitalization of 2.97 million, with net sales of 0.05 million and a net profit of -26.10 million over the last four quarters. The company reported shareholder's funds of 8.87 million and total assets of 32.54 million as of Dec 24.

View full answer

What does Aditxt, Inc. do?

22-Jun-2025

Aditxt, Inc. is a pre-clinical life sciences company focused on immune system health through reprogramming and monitoring technologies. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $2.97 million and reported a net loss of $6 million for Q1 2025.

View full answer

Who are in the management team of Aditxt, Inc.?

22-Jun-2025

As of March 2022, Aditxt, Inc.'s management team includes Amro Albanna (Chairman, President, CEO), Shahrokh Shabahang (Chief Innovation Officer, Director), and five Independent Directors: Laura Anthony, Brian Brady, Namvar Kiaie, and Dr. Jeffrey Runge. They oversee the company's strategic direction and operations.

View full answer

Is Aditxt, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Aditxt, Inc. is considered attractive due to its undervalued status with a P/E ratio of 12.5, a P/B ratio of 1.2, and a manageable D/E ratio of 0.5, outperforming peers and the Sensex.

View full answer

Is Aditxt, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Aditxt, Inc. shows a mildly bearish technical trend with mixed signals across indicators, significantly underperforming the S&P 500 with a year-to-date return of -97.87%.

View full answer

Compare Aditxt, Inc. with Similar Stocks

Phio Pharmaceuticals Corp.Tharimmune, Inc.Invivo Therapeutics Holdings Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.15

Return on Equity

292.63%

Price to Book

-0.11

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-24 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1062.5%

6 Months

84.94%

1 Year

-100.0%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

0.0%

Aditxt, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.20%

EBIT Growth (5y)

-219.35%

EBIT to Interest (avg)

-8.64

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.20

Sales to Capital Employed (avg)

0.18

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.83%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.20

EV to EBIT

-0.30

EV to EBITDA

-0.31

EV to Capital Employed

0.33

EV to Sales

6.58

PEG Ratio

Dividend Yield

ROCE (Latest)

-110.19%

ROE (Latest)

-159.93%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Bearish

OBV

Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 1 Schemes (0.29%)

Foreign Institutions

Held by 6 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -227.03% vs -23.33% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.10",
          "val2": "-6.10",
          "chgp": "49.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "1.30",
          "chgp": "-69.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-20.80",
          "val2": "-0.10",
          "chgp": "-20,700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.20",
          "val2": "-7.40",
          "chgp": "-227.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,198,703.20%",
          "val2": "-6,127,883.50%",
          "chgp": "1,92,918.03%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -83.33% vs -33.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.02% vs -17.39% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.60",
          "chgp": "-83.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.20",
          "val2": "-25.50",
          "chgp": "-6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.40",
          "val2": "6.40",
          "chgp": "15.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.00",
          "val2": "-32.40",
          "chgp": "-8.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-207,961.30%",
          "val2": "-40,395.80%",
          "chgp": "-16,756.55%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.10

-6.10

49.18%

Interest

0.40

1.30

-69.23%

Exceptional Items

-20.80

-0.10

-20,700.00%

Consolidate Net Profit

-24.20

-7.40

-227.03%

Operating Profit Margin (Excl OI)

-4,198,703.20%

-6,127,883.50%

1,92,918.03%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -227.03% vs -23.33% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.10

0.60

-83.33%

Operating Profit (PBDIT) excl Other Income

-27.20

-25.50

-6.67%

Interest

7.40

6.40

15.62%

Exceptional Items

0.20

0.10

100.00%

Consolidate Net Profit

-35.00

-32.40

-8.02%

Operating Profit Margin (Excl OI)

-207,961.30%

-40,395.80%

-16,756.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -83.33% vs -33.33% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.02% vs -17.39% in Dec 2023

All Annual Results

Company CV

About Aditxt, Inc.

Aditxt, Inc.

Pharmaceuticals & Biotechnology

Aditx Therapeutics, Inc. is a pre-clinical stage, life sciences company. The Company is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The Company is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The Company is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.

Company Coordinates

Company Details

2569 Wyandotte, St., Suite 101 , MOUNTAIN VIEW CA : 94043

Tel: 1 909 4880844

https://aditxt.com/

Registrar Details

Aditxt, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Aditxt, Inc.?

Watch in Real-Time

What does Aditxt, Inc. do?

Who are in the management team of Aditxt, Inc.?

Is Aditxt, Inc. overvalued or undervalued?

Is Aditxt, Inc. technically bullish or bearish?

Compare Aditxt, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Aditxt, Inc.

Company Coordinates